Cotadutide
Chronic Kidney Disease
AstraZenecaprotein_peptidePhase 1Active
CC
44/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 81/ 100
Competitive context
29 Active assets in the Chronic Kidney Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
SODIUM FERRIC GLUCONATE Watson Pharmaceuticals | Phase 4 | BBB |
IRON(II) SULPHATE (1:1), HEPTAHYDRATE Watson Pharmaceuticals | Phase 4 | BBB |
Semaglutide Institute of Liver and Biliary Sciences, India | Phase 4 | BBB |
Plavix Hospital Alemão Oswaldo Cruz | Phase 4 | BB |
Acetylsalicylic Acid Hospital Alemão Oswaldo Cruz | Phase 4 | BB |
View all 50 →
Same molecule, other indications
Cotadutide is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →